3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Hepatocellular
129
Carcinoma, Renal Cell
36
Parkinson Disease 4, Autosomal Dominant Lewy Body
31
Neoplasms
27
Cholangiocarcinoma
23
Endometrial Neoplasms
19
Liver Neoplasms
16
Melanoma
15
Thyroid Neoplasms
13
Stomach Neoplasms
13
Carcinoma, Non-Small-Cell Lung
13
Biliary Tract Neoplasms
12
Neoplasm Metastasis
9
Squamous Cell Carcinoma of Head and Neck
8
Recurrence
8
Ovarian Neoplasms
8
Breast Neoplasms
8
Uterine Cervical Neoplasms
7
Triple Negative Breast Neoplasms
5
Thyroid Carcinoma, Anaplastic
5
Small Cell Lung Carcinoma
5
Neuroendocrine Tumors
5
Esophageal Squamous Cell Carcinoma
5
Colorectal Neoplasms
5
Pancreatic Neoplasms
4
Kidney Neoplasms
4
Carcinoma, Transitional Cell
4
Adenocarcinoma
4
Thyroid Cancer, Papillary
3
Solid Tumors
3
Interventions
belzutifan
4
gallium Ga 68 dotatate
3
Everolimus
2
vatalanib
1
tanespimycin
1
spartalizumab
1
palbociclib
1
lenvatinib
1
cabozantinib
1
Vorinostat
1
Sunitinib
1
Ranibizumab
1
Propranolol
1
PT2385
1
Oxygen-15
1
Nivolumab
1
Magnetic Resonance Spectroscopy
1
Fluorodeoxyglucose F18
1
Bevacizumab
1
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
von Hippel-Lindau Disease
×
lenvatinib
×
Clear all
NCT07405164
2026-05-29
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3
Recruiting
450 enrolled